One day, patients may be able to monitor their body’s response to cancer therapy just by having their blood drawn. A new study, led by Amy Herr, faculty engineer in the Biological Systems & Engineering Division, has taken an important step in that direction by measuring a panel of cancer proteins in rare, individual tumor cells that float in the blood. She says, “Microfluidic design was key in this study.” Read more in Berkeley News.